ACURX PHARMACEUTICALS INC (ACXP)
US00510M1045 - Common Stock
ACXP gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. ACXP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ACXP is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ACXP had negative earnings in the past year.
ACXP had a negative operating cash flow in the past year.
In the past 5 years ACXP always reported negative net income.
ACXP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ACXP (-274.72%) is worse than 93.87% of its industry peers.
With a Return On Equity value of -616.97%, ACXP is not doing good in the industry: 81.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -274.72% | ||
| ROE | -616.97% | ||
| ROIC | N/A |
ROA(3y)-138.07%
ROA(5y)-158.29%
ROE(3y)-193.43%
ROE(5y)-294.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ACXP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ACXP has more shares outstanding
There is no outstanding debt for ACXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ACXP has an Altman-Z score of -21.34. This is a bad value and indicates that ACXP is not financially healthy and even has some risk of bankruptcy.
ACXP's Altman-Z score of -21.34 is on the low side compared to the rest of the industry. ACXP is outperformed by 87.57% of its industry peers.
ACXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -21.34 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ACXP has a Current Ratio of 1.80. This is a normal value and indicates that ACXP is financially healthy and should not expect problems in meeting its short term obligations.
ACXP has a worse Current ratio (1.80) than 78.74% of its industry peers.
A Quick Ratio of 1.80 indicates that ACXP should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.80, ACXP is doing worse than 77.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
The earnings per share for ACXP have decreased by -2.86% in the last year.
EPS 1Y (TTM)-2.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -24.55% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.29%
EPS Next 2Y-14.29%
EPS Next 3Y-18.93%
EPS Next 5Y-24.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ACXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACXP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ACXP's earnings are expected to decrease with -18.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.29%
EPS Next 3Y-18.93%
5. Dividend
5.1 Amount
ACXP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACURX PHARMACEUTICALS INC
NASDAQ:ACXP (1/10/2025, 9:39:54 AM)
0.7715
+0.02 (+2.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners7.43%
Inst Owner Change0%
Ins Owners14.8%
Ins Owner Change0%
Market Cap13.03M
Analysts82.5
Price Target11.41 (1378.94%)
Short Float %3.47%
Short Ratio3.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.4%
Min EPS beat(2)-15.86%
Max EPS beat(2)16.67%
EPS beat(4)1
Avg EPS beat(4)-13.27%
Min EPS beat(4)-39.52%
Max EPS beat(4)16.67%
EPS beat(8)4
Avg EPS beat(8)-0.43%
EPS beat(12)7
Avg EPS beat(12)6.71%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.86%
EPS NY rev (1m)0%
EPS NY rev (3m)5.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.89 | ||
| P/tB | 4.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.08
EYN/A
EPS(NY)-1.49
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -274.72% | ||
| ROE | -616.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-138.07%
ROA(5y)-158.29%
ROE(3y)-193.43%
ROE(5y)-294.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | -21.34 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.17%
EPS Next Y25.29%
EPS Next 2Y-14.29%
EPS Next 3Y-18.93%
EPS Next 5Y-24.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.36%
OCF growth 3YN/A
OCF growth 5YN/A